First evaluation of the performance of portable IGRA, QIAreach® QuantiFERON®-TB in intermediate TB incidence setting.
Diagnosis and treatment of tuberculosis infection (TBI) are the core elements of tuberculosis elimination. Interferon gamma release assays have advantages over the tuberculin skin test, although their implementation in low-resource settings is challenging. The performance of a novel digital lateral...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2023-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0279882 |
_version_ | 1797852094724571136 |
---|---|
author | Zirwatul Adilah Aziz Noorliza Mohamad Noordin Wan Mazlina Wan Mohd Mohd Amin Kasim |
author_facet | Zirwatul Adilah Aziz Noorliza Mohamad Noordin Wan Mazlina Wan Mohd Mohd Amin Kasim |
author_sort | Zirwatul Adilah Aziz |
collection | DOAJ |
description | Diagnosis and treatment of tuberculosis infection (TBI) are the core elements of tuberculosis elimination. Interferon gamma release assays have advantages over the tuberculin skin test, although their implementation in low-resource settings is challenging. The performance of a novel digital lateral flow assay QIAreach® QuantiFERON®-TB (QIAreach QFT) against the QuantiFERON®-TB Gold Plus (QFT-Plus) assay was evaluated in an intermediate incidence setting (Malaysia) according to the manufacturer's instructions. Individuals aged 4-82 years, who were candidates for TB infection screening for contact investigation were prospectively recruited. On 196 samples, the QIAreach-QFT showed a positive percent agreement (sensitivity) was 96.5% (CI 87.9-99.6%), a negative percent agreement (specificity) 94.2% (CI 88.4% to 97.6%) and an overall percentage of agreement was 94.9% (95% CI 90.6-97.6%) with a Cohen's κ of 0,88. Out of 196, 5.6% (11/196) samples gave an error result on QIAreach-QFT and 4.1% (8/196) samples gave indeterminate result on QFT-plus. The TTR for QIAreach QFT positive samples varied from 210-1200 seconds (20 min) and significantly correlated with IFN-γ level of QFT-Plus. QIAreach QFT could be considered an accurate and reliable point-of-need test to diagnose TB infection helping to achieve the WHO End TB programme goals even in decentralised settings where laboratory expertise and infrastructure may be limited. |
first_indexed | 2024-04-09T19:28:30Z |
format | Article |
id | doaj.art-163399aef3bb4a32890132836c00e476 |
institution | Directory Open Access Journal |
issn | 1932-6203 |
language | English |
last_indexed | 2024-04-09T19:28:30Z |
publishDate | 2023-01-01 |
publisher | Public Library of Science (PLoS) |
record_format | Article |
series | PLoS ONE |
spelling | doaj.art-163399aef3bb4a32890132836c00e4762023-04-05T05:31:30ZengPublic Library of Science (PLoS)PLoS ONE1932-62032023-01-01182e027988210.1371/journal.pone.0279882First evaluation of the performance of portable IGRA, QIAreach® QuantiFERON®-TB in intermediate TB incidence setting.Zirwatul Adilah AzizNoorliza Mohamad NoordinWan Mazlina Wan MohdMohd Amin KasimDiagnosis and treatment of tuberculosis infection (TBI) are the core elements of tuberculosis elimination. Interferon gamma release assays have advantages over the tuberculin skin test, although their implementation in low-resource settings is challenging. The performance of a novel digital lateral flow assay QIAreach® QuantiFERON®-TB (QIAreach QFT) against the QuantiFERON®-TB Gold Plus (QFT-Plus) assay was evaluated in an intermediate incidence setting (Malaysia) according to the manufacturer's instructions. Individuals aged 4-82 years, who were candidates for TB infection screening for contact investigation were prospectively recruited. On 196 samples, the QIAreach-QFT showed a positive percent agreement (sensitivity) was 96.5% (CI 87.9-99.6%), a negative percent agreement (specificity) 94.2% (CI 88.4% to 97.6%) and an overall percentage of agreement was 94.9% (95% CI 90.6-97.6%) with a Cohen's κ of 0,88. Out of 196, 5.6% (11/196) samples gave an error result on QIAreach-QFT and 4.1% (8/196) samples gave indeterminate result on QFT-plus. The TTR for QIAreach QFT positive samples varied from 210-1200 seconds (20 min) and significantly correlated with IFN-γ level of QFT-Plus. QIAreach QFT could be considered an accurate and reliable point-of-need test to diagnose TB infection helping to achieve the WHO End TB programme goals even in decentralised settings where laboratory expertise and infrastructure may be limited.https://doi.org/10.1371/journal.pone.0279882 |
spellingShingle | Zirwatul Adilah Aziz Noorliza Mohamad Noordin Wan Mazlina Wan Mohd Mohd Amin Kasim First evaluation of the performance of portable IGRA, QIAreach® QuantiFERON®-TB in intermediate TB incidence setting. PLoS ONE |
title | First evaluation of the performance of portable IGRA, QIAreach® QuantiFERON®-TB in intermediate TB incidence setting. |
title_full | First evaluation of the performance of portable IGRA, QIAreach® QuantiFERON®-TB in intermediate TB incidence setting. |
title_fullStr | First evaluation of the performance of portable IGRA, QIAreach® QuantiFERON®-TB in intermediate TB incidence setting. |
title_full_unstemmed | First evaluation of the performance of portable IGRA, QIAreach® QuantiFERON®-TB in intermediate TB incidence setting. |
title_short | First evaluation of the performance of portable IGRA, QIAreach® QuantiFERON®-TB in intermediate TB incidence setting. |
title_sort | first evaluation of the performance of portable igra qiareach r quantiferon r tb in intermediate tb incidence setting |
url | https://doi.org/10.1371/journal.pone.0279882 |
work_keys_str_mv | AT zirwatuladilahaziz firstevaluationoftheperformanceofportableigraqiareachquantiferontbinintermediatetbincidencesetting AT noorlizamohamadnoordin firstevaluationoftheperformanceofportableigraqiareachquantiferontbinintermediatetbincidencesetting AT wanmazlinawanmohd firstevaluationoftheperformanceofportableigraqiareachquantiferontbinintermediatetbincidencesetting AT mohdaminkasim firstevaluationoftheperformanceofportableigraqiareachquantiferontbinintermediatetbincidencesetting |